Acer Therapeutics Inc. announced the appointment of William T. Andrews, M.D., FACP as Chief Medical Officer of the Company to succeed Robert D. Steiner, M.D. in that position. Dr. Andrews joins Acer Therapeutics as Chief Medical Officer after having worked in the biotech/pharmaceutical industry for 17 years in both Clinical Development and Medical Affairs in multiple therapeutic areas, with a focus and extensive experience in rare diseases. Dr. Andrews has significant medical marketplace and product launch experience, having served as the medical lead for six product launches, including Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®. Most recently, he provided strategic consulting services to rare disease companies in Clinical Development, Medical Affairs, Go-To-Market/Launch planning, and Business Development/Corporate Strategy.